Related references
Note: Only part of the references are listed.Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results
Alexander Roeth et al.
HAEMATOLOGICA (2022)
O, wind, if winter comes ... will symptoms be far behind? Exploring the seasonality (or lack thereof) and management of cold agglutinin disease
Christopher J. Patriquin et al.
TRANSFUSION (2022)
Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia
Morie A. Gertz
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2022)
ARGX-117, a therapeutic complement inhibiting antibody targeting C2
Inge Van de Walle et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
How I treat cold agglutinin disease
Sigbjorn Berentsen
BLOOD (2021)
Inhibition of Complement Cis By Suti limab in Patients h Cold Agglutinin Disease (CAD): Efficacy and Safety Results om the Rando ized, Placebo-Controlled Phase 3 CADENZA Study
Alexander Roeth et al.
BLOOD (2021)
Autoimmune Hemolytic Anemias
Sigbjorn Berentsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sutimlimab in Cold Agglutinin Disease
Alexander Roeth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome
Marit Jalink et al.
BLOOD (2021)
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
Ulrich Jaeger et al.
BLOOD REVIEWS (2020)
Cold agglutinin disease revisited: a multinational, observational study of 232 patients
Sigbjorn Berentsen et al.
BLOOD (2020)
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
Sigbjorn Berentsen
FRONTIERS IN IMMUNOLOGY (2020)
Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy
Oliver Tomkins et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program
Georg Gelbenegger et al.
BLOOD ADVANCES (2020)
Cold agglutinins: fending off the attack
Sigbjorn Berentsen
BLOOD (2019)
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
Ulrich Jaeger et al.
BLOOD (2019)
Novel insights into the treatment of complement-mediated hemolytic anemias
Sigbjorn Berentsen et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study
Giuseppe Rossi et al.
BLOOD (2018)
A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway
Johann Bartko et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease
Sigbjorn Berentsen
SEMINARS IN HEMATOLOGY (2018)
Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial
Alexander Roeth et al.
BLOOD ADVANCES (2018)
Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease
Agnieszka Malecka et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases
Janice A. Lansita et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2017)
Role of plasma cells in Waldenstrom macroglobulinaemia
Ali El-Ayoubi et al.
PATHOLOGY (2017)
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial
Jakob Muehlbacher et al.
TRANSPLANTATION (2017)
Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial
Sigbjorn Berentsen et al.
BLOOD (2017)
ANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation Triggered By Cold Agglutinins in Human Disease
Morie A. Gertz et al.
BLOOD (2016)
Complement An Overview for the Clinician
Juan Carlos Varela et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins
Ju Shi et al.
BLOOD (2014)
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
Wilma Barcellini et al.
BLOOD (2014)
Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma
Ulla Randen et al.
HAEMATOLOGICA (2014)
C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia
Diana Wouters et al.
BLOOD (2013)
Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia
Sigbjorn Berentsen et al.
BLOOD REVIEWS (2012)
Pathogenic Long-Lived Plasma Cells and Their Survival Niches in Autoimmunity, Malignancy, and Allergy
Oliver Winter et al.
JOURNAL OF IMMUNOLOGY (2012)
Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale in Patients with Moderately to Severely Active Systemic Lupus Erythematosus, Participating in a Clinical Trial
Jin-Shei Lai et al.
JOURNAL OF RHEUMATOLOGY (2011)
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease
Sigbjorn Berentsen et al.
BLOOD (2010)
Clinical immunology of chronic cold agglutinin disease
Elling Ulvestad et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Complete complement deficiency in a large cohort of familial systemic lupus erythematosus
R. Aggarwal et al.
LUPUS (2010)
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky et al.
BLOOD (2008)
Rituximab in chronic cold agglutinin disease:: a prospective study of 20 patients
C Schöllkopf et al.
LEUKEMIA & LYMPHOMA (2006)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
S Berentsen et al.
BLOOD (2004)
Share Paper
